Figure 2.

Selective PTK inhibitors suggest that a Src family kinase inhibits PMCA in DRG neurons. A, Plot summarizes changes in [Ca²⁺]_i recovery kinetics (normalized k) for cells treated with the Src family tyrosine kinase inhibitor PP2 (10 μm; open circles, n = 5) or its inactive analog PP3 (10 μm; solid squares, n = 5). Drug was present during the time indicated by the horizontal bar. Data are mean ± SE. *p < 0.05, **p < 0.01, ***p < 0.001 relative to PP3, repeated-measures ANOVA with Bonferroni post hoc test. B, Bar graph summarizes percentage change in recovery rate for untreated cells (control) (from Fig. 1C), or cells treated with 100 μm AG18 (AG18) (from Fig. 1A–C) (n = 5), 10 μm PP2 (n = 5), 10 μm PP3 (n = 5), 10 μm SU6656 (n = 5), or 10 μm SKI-1 (n = 4). Percentage change in recovery rate = 100[(k_drug − k_control)/k_control], where k_control is the mean of the three k values determined before drug application (t = 0, 4, and 8 min) and k_drug is the mean of the last three k values following drug application (t = 24, 28, and 32 min). Initial rate constants (k) for the cells before their respective treatments were 4.1 ± 0.5, 3.9 ± 0.6, 4.1 ± 0.2, 4.4 ± 0.3, 6.3 ± 0.7, and 6 ± 1 min⁻¹. **p < 0.01, ***p < 0.001 relative to control, ANOVA with Bonferroni post hoc test.